Our new Trends in Cancer commentary explores how next-gen RAS inhibitors are rewriting the rules of precision oncology - from allele-specific RNAi to dual-state KRAS degraders.
🔗 authors.elsevier.com/a/1m0YQ8Z12y...
#RAS #PrecisionOncology #DrugDevelopment
Our new Trends in Cancer commentary explores how next-gen RAS inhibitors are rewriting the rules of precision oncology - from allele-specific RNAi to dual-state KRAS degraders.
🔗 authors.elsevier.com/a/1m0YQ8Z12y...
#RAS #PrecisionOncology #DrugDevelopment